ENTITY

Aethlon Medical (AEMD US)

28
Analysis
Health Care • United States
Aethlon Medical, Inc. operates as a medical device company. The Company provides a platform to develop medical devices that target the selective removal of disease-promoting particles from the circulatory system. Aethlon Medical develops medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.
more
bullish•Aethlon Medical
•21 Oct 2025 22:00•Issuer-paid

Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended

Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended, suggesting a potential benefit to...

Share
bullish•Aethlon Medical
•11 Oct 2025 07:00•Issuer-paid

Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended

Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended, suggesting a potential benefit to...

Share
bullish•Aethlon Medical
•11 Oct 2025 02:00•Issuer-paid

Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended

Levels of certain harmful particles typically returned to pre-treatment levels 1-3 weeks after treatment ended, suggesting a potential benefit to...

Share
bullish•Aethlon Medical
•19 Aug 2025 22:00•Issuer-paid

With the timeline to launch a study in India similar to the one being conducted in Australia significantly longer than AEMD had initially anticipated

With the timeline to launch a study in India similar to the one being conducted in Australia significantly longer than AEMD had initially...

Share
bullish•Aethlon Medical
•18 Jul 2025 00:00•Issuer-paid

The independent Data Safety Monitoring Board (DSMB) overseeing the AEMD clinical trial has completed its scheduled safety review

The independent Data Safety Monitoring Board (DSMB) overseeing the AEMD clinical trial has completed its scheduled safety review, recommending...

Share
x